市場調査レポート
商品コード
1420111

グルカゴン様ペプチド1(GLP-1)作動薬の世界市場:タイプ別、最終用途別、流通経路別、投与経路別、地域別、国別の分析、市場考察、予測

Global Glucagon-Like Peptide 1 Agonist market : Analysis by Type, End-Use, By Distribution Channel, By Route of Administration, By Region, By Country: Market Insights and Forecast

出版日: | 発行: Azoth Analytics | ページ情報: 英文 250 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.31円
グルカゴン様ペプチド1(GLP-1)作動薬の世界市場:タイプ別、最終用途別、流通経路別、投与経路別、地域別、国別の分析、市場考察、予測
出版日: 2024年02月01日
発行: Azoth Analytics
ページ情報: 英文 250 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のグルカゴン様ペプチド1(GLP-1)作動薬の市場規模は、2020年~2023年にCAGRで20.6%の成長を示しました。2022年の市場規模は187億5,000万米ドルであり、2030年に1,335億米ドルに達する見込みです。GLP-1作動薬の需要は世界的に拡大しており、先進地域と発展途上地域がともに市場成長に寄与しています。新興経済国ではT2DMの有病率が上昇しており、GLP-1作動薬治療を含む効果的な糖尿病管理戦略の必要性が高まっています。市場には、短時間作用型と長時間作用型のさまざまなGLP-1作動薬があり、医療提供者や患者にさまざまな選択肢を提供しています。これらの薬剤は皮下注射または場合によって経口投与されます。

GLP-1作動薬はT2DM患者の血糖制御の改善に有効であることが知られており、しばしばHbA1c値や空腹時の血糖値の低下をもたらします。さらに、これらの薬剤は体重減少を伴うため、肥満の糖尿病患者にとって特に有益です。

いくつかのGLP-1作動薬は、臨床試験において、心臓発作、脳卒中、心血管死などの主要有害心血管イベント(MACE)を減少させるなど、心血管系に有益であることが示されています。これらの調査結果は、T2DMと心血管疾患(CVD)の持病がある、あるいは心血管リスクが高い患者におけるGLP-1作動薬の採用拡大に寄与しています。

GLP-1作動薬は主に皮下注射で投与されますが、患者の服薬アドヒアランスと利便性を向上させるため、経口製剤や週1回注射などの代替投与法の開発が進められています。これらの技術革新は、治療アドヒアランスに対する潜在的な障壁に対処し、患者の満足度を高めることを目的としています。

当レポートでは、世界のグルカゴン様ペプチド1(GLP-1)作動薬市場について調査し、市場規模と予測、地域とセグメントの分析、主要動向と機会などの情報を提供しています。

目次

第1章 市場の背景

  • 範囲と製品の見通し
  • エグゼクティブサマリー
  • 調査手法

第2章 戦略的推奨事項

第3章 世界のグルカゴン様ペプチド1(GLP-1)作動薬市場:実績と予測(2020年~2030年)

  • グルカゴン様ペプチド1(GLP-1)作動薬市場に対するマクロ経済要因の影響の分析
  • GLP-1作動薬市場のパイプライン分析
  • 世界の肥満統計(2022年)
  • 糖尿病統計
  • 世界のグルカゴン様ペプチド1(GLP-1)作動薬市場:ダッシュボード
  • 世界のグルカゴン様ペプチド1(GLP-1)作動薬市場:市場金額の評価(2020年~2030年)
  • グルカゴン様ペプチド1(GLP-1)作動薬市場に対するCOVID-19の影響
  • 世界のグルカゴン様ペプチド1(GLP-1)作動薬市場セグメンテーション:タイプ別
    • 世界のグルカゴン様ペプチド1(GLP-1)作動薬市場:タイプ別、概要
    • 世界のグルカゴン様ペプチド1(GLP-1)作動薬の市場規模:チルゼパチド(金額)(2020年~2030年)
    • 世界のグルカゴン様ペプチド1(GLP-1)作動薬の市場規模:セマグルチド(金額)(2020年~2030年)
    • 世界のグルカゴン様ペプチド1(GLP-1)作動薬の市場規模:デュラグルチド(金額)(2020年~2030年)
    • 世界のグルカゴン様ペプチド1(GLP-1)作動薬の市場規模:その他タイプ(金額)(2020年~2030年)
  • 世界のグルカゴン様ペプチド1(GLP-1)作動薬市場セグメンテーション:流通チャネル別
    • 世界のグルカゴン様ペプチド1(GLP-1)作動薬市場:流通チャネル別、概要
    • 世界のグルカゴン様ペプチド1(GLP-1)作動薬の市場規模:診療所(金額)(2020年~2030年)
    • 世界のグルカゴン様ペプチド1(GLP-1)作動薬の市場規模:外来手術センター(金額)(2020年~2030年)
    • 世界のグルカゴン様ペプチド1(GLP-1)作動薬の市場規模:病院(金額)(2020年~2030年)
  • 世界のグルカゴン様ペプチド1(GLP-1)作動薬市場セグメンテーション:投与経路別
    • 世界のグルカゴン様ペプチド1(GLP-1)作動薬市場:投与経路別、概要
    • 世界のグルカゴン様ペプチド1(GLP-1)作動薬の市場規模:経口(金額)(2020年~2030年)
    • 世界のグルカゴン様ペプチド1(GLP-1)作動薬の市場規模:非経口(金額)(2020年~2030年)
  • 世界のグルカゴン様ペプチド1(GLP-1)作動薬市場セグメンテーション:最終用途別
    • 世界のグルカゴン様ペプチド1(GLP-1)作動薬市場:最終用途別、概要
    • 世界のグルカゴン様ペプチド1(GLP-1)作動薬の市場規模:2型糖尿病(金額)(2020年~2030年)
    • 世界のグルカゴン様ペプチド1(GLP-1)作動薬の市場規模:NASH(金額)(2020年~2030年)
    • 世界のグルカゴン様ペプチド1(GLP-1)作動薬の市場規模:肥満(金額)(2020年~2030年)

第4章 世界のグルカゴン様ペプチド1(GLP-1)作動薬市場:地域の分析

  • 研究の地域範囲
  • 地域のスナップショット

第5章 南北アメリカのグルカゴン様ペプチド1(GLP-1)作動薬市場:実績と予測(2020年~2030年)

  • 南北アメリカのグルカゴン様ペプチド1(GLP-1)作動薬市場:スナップショット
  • 南北アメリカのグルカゴン様ペプチド1(GLP-1)作動薬市場:市場金額の評価(2020年~2030年)
  • 南北アメリカのグルカゴン様ペプチド1(GLP-1)作動薬市場:主な要因
  • 南北アメリカのグルカゴン様ペプチド1(GLP-1)作動薬市場:市場金額の評価
  • 南北アメリカのグルカゴン様ペプチド1(GLP-1)作動薬市場:市場力学
  • 南北アメリカのグルカゴン様ペプチド1(GLP-1)作動薬市場セグメンテーション:流通チャネル別
  • 南北アメリカのグルカゴン様ペプチド1(GLP-1)作動薬市場セグメンテーション:投与経路別
  • 南北アメリカのグルカゴン様ペプチド1(GLP-1)作動薬市場セグメンテーション:最終用途別
  • 南北アメリカのグルカゴン様ペプチド1(GLP-1)作動薬市場セグメンテーション:国別
    • 南北アメリカのグルカゴン様ペプチド1(GLP-1)作動薬市場:国別、概要
    • 米国のグルカゴン様ペプチド1(GLP-1)作動薬市場:市場規模とCAGR(2020年~2030年)
    • カナダのグルカゴン様ペプチド1(GLP-1)作動薬市場:市場規模とCAGR(2020年~2030年)
    • その他の南北アメリカのグルカゴン様ペプチド1(GLP-1)作動薬市場:市場規模とCAGR(2020年~2030年)

第6章 欧州のグルカゴン様ペプチド1(GLP-1)作動薬市場:実績と予測(2020年~2030年)

  • 欧州のグルカゴン様ペプチド1(GLP-1)作動薬市場:スナップショット
  • 欧州のグルカゴン様ペプチド1(GLP-1)作動薬市場:市場金額の評価(2020年~2030年)
  • 欧州のグルカゴン様ペプチド1(GLP-1)作動薬市場:主な要因
  • 欧州のグルカゴン様ペプチド1(GLP-1)作動薬市場:市場金額の評価
  • 欧州のグルカゴン様ペプチド1(GLP-1)作動薬市場:市場力学
  • 欧州のグルカゴン様ペプチド1(GLP-1)作動薬市場セグメンテーション:流通チャネル別
  • 欧州のグルカゴン様ペプチド1(GLP-1)作動薬市場セグメンテーション:投与経路別
  • 欧州のグルカゴン様ペプチド1(GLP-1)作動薬市場セグメンテーション:最終用途別
  • 欧州のグルカゴン様ペプチド1(GLP-1)作動薬市場セグメンテーション:国別
    • 欧州のグルカゴン様ペプチド1(GLP-1)作動薬市場:国別、概要
    • 英国のグルカゴン様ペプチド1(GLP-1)作動薬市場:市場規模とCAGR(2020年~2030年)
    • ドイツのグルカゴン様ペプチド1(GLP-1)作動薬市場:市場規模とCAGR(2020年~2030年)
    • フランスのグルカゴン様ペプチド1(GLP-1)作動薬市場:市場規模とCAGR(2020年~2030年)
    • イタリアのグルカゴン様ペプチド1(GLP-1)作動薬市場:市場規模とCAGR(2020年~2030年)
    • その他の欧州のグルカゴン様ペプチド1(GLP-1)作動薬市場:市場規模とCAGR(2020年~2030年)

第7章 アジア太平洋のグルカゴン様ペプチド1(GLP-1)作動薬市場:実績と予測(2020年~2030年)

  • アジア太平洋のグルカゴン様ペプチド1(GLP-1)作動薬市場:スナップショット
  • アジア太平洋のグルカゴン様ペプチド1(GLP-1)作動薬市場:市場金額の評価(2020年~2030年)
  • アジア太平洋のグルカゴン様ペプチド1(GLP-1)作動薬市場:主な要因
  • アジア太平洋のグルカゴン様ペプチド1(GLP-1)作動薬市場:市場金額の評価
  • アジア太平洋のグルカゴン様ペプチド1(GLP-1)作動薬市場:市場力学
  • アジア太平洋のグルカゴン様ペプチド1(GLP-1)作動薬市場セグメンテーション:流通チャネル別
  • アジア太平洋のグルカゴン様ペプチド1(GLP-1)作動薬市場セグメンテーション:投与経路別
  • アジア太平洋のグルカゴン様ペプチド1(GLP-1)作動薬市場セグメンテーション:最終用途別
  • アジア太平洋のグルカゴン様ペプチド1(GLP-1)作動薬市場セグメンテーション:国別
    • アジア太平洋のグルカゴン様ペプチド1(GLP-1)作動薬市場:国別、概要
    • 中国のグルカゴン様ペプチド1(GLP-1)作動薬市場:市場規模とCAGR(2020年~2030年)
    • 日本のグルカゴン様ペプチド1(GLP-1)作動薬市場:市場規模とCAGR(2020年~2030年)
    • 韓国のグルカゴン様ペプチド1(GLP-1)作動薬市場:市場規模とCAGR(2020年~2030年)
    • インドのグルカゴン様ペプチド1(GLP-1)作動薬市場:市場規模とCAGR(2020年~2030年)
    • その他のアジア太平洋のグルカゴン様ペプチド1(GLP-1)作動薬市場:市場規模とCAGR(2020年~2030年)

第8章 中東・アフリカのグルカゴン様ペプチド1(GLP-1)作動薬市場:実績と予測(2020年~2030年)

  • 中東・アフリカのグルカゴン様ペプチド1(GLP-1)作動薬市場:スナップショット
  • 中東・アフリカのグルカゴン様ペプチド1(GLP-1)作動薬市場:市場金額の評価(2020年~2030年)
  • 中東・アフリカのグルカゴン様ペプチド1(GLP-1)作動薬市場:主な要因
  • 中東・アフリカのグルカゴン様ペプチド1(GLP-1)作動薬市場:市場金額の評価
  • 中東・アフリカのグルカゴン様ペプチド1(GLP-1)作動薬市場:市場力学
  • 中東・アフリカのグルカゴン様ペプチド1(GLP-1)作動薬市場セグメンテーション:流通チャネル別
  • 中東・アフリカのグルカゴン様ペプチド1(GLP-1)作動薬市場セグメンテーション:投与経路別
  • 中東・アフリカのグルカゴン様ペプチド1(GLP-1)作動薬市場セグメンテーション:最終用途別

第9章 市場力学

  • 世界のグルカゴン様ペプチド1(GLP-1)作動薬市場に対する市場力学の影響の評価
  • 促進要因
  • 抑制要因
  • 動向

第10章 産業エコシステム分析

  • ポーターのファイブフォース分析モデル

第11章 競合ポジショニング

  • 企業の製品ポジショニング
  • グルカゴン様ペプチド1(GLP-1)作動薬市場の市場シェア分析
  • 企業プロファイル
    • Eli Lilly and Company
    • Pfizer
    • Sanofi
    • AstraZeneca PLC
    • Boehringer Ingelheim
    • Novo Nordisk
図表

List of Figures

List of Figures

  • Figure 1: Global Obesity Statistics 2022 (In Millions)
  • Figure 2: People with diabetes in Thousands, (20-79 y)
  • Figure 3: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Value, 2020-2022 (USD Million)
  • Figure 4: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Value, 2023-2030 (USD Million)
  • Figure 5: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market CAGR (%), By Value, 2020-2023, 2024-2030
  • Figure 6: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Tirzepatide, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 7: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Absolute Opportunity, By Tirzepatide, 2020-2030 (USD Million)
  • Figure 8: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Semaglutide, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 9: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Absolute Opportunity, By Semaglutide, 2020-2030 (USD Million)
  • Figure 10: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Dulaglutide, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 11: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Absolute Opportunity, By Dulaglutide, 2020-2030 (USD Million)
  • Figure 12: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Other Types, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 13: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Absolute Opportunity, By Other Types, 2020-2030 (USD Million)
  • Figure 14: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Clinics, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 15: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Absolute Opportunity, By Clinics, 2020-2030 (USD Million)
  • Figure 16: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 17: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Absolute Opportunity, By Ambulatory Surgical Centers, 2020-2030 (USD Million)
  • Figure 18: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 19: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Absolute Opportunity, By Hospitals, 2020-2030 (USD Million)
  • Figure 20: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 21: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Absolute Opportunity, By Oral, 2020-2030 (USD Million)
  • Figure 22: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 23: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Absolute Opportunity, By Parenteral, 2020-2030 (USD Million)
  • Figure 24: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Type 2 Diabetes, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 25: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Absolute Opportunity, By Type 2 Diabetes, 2020-2030 (USD Million)
  • Figure 26: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By NASH, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 27: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Absolute Opportunity, By NASH, 2020-2030 (USD Million)
  • Figure 28: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Obesity, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 29: Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Absolute Opportunity, By Obesity, 2020-2030 (USD Million)
  • Figure 30: Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Value, 2020H-2030F (USD Million)
  • Figure 31: Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By End-Use, 2022 (%)
  • Figure 32: Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Clinics, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 33: Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 34: Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 35: Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 36: Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 37: Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Type 2 Diabetes, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 38: Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By NASH, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 39: Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Obesity, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 40: United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Value, 2020-2030 (USD Million & CAGR)
  • Figure 41: United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market Value, By End-Use, 2022 (USD Million)
  • Figure 42: United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Distribution Channel, 2022 (%)
  • Figure 43: United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Route of Administration, By Value, 2022 (%)
  • Figure 44: United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By End-Use, 2022 (%)
  • Figure 45: Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Value, 2020-2030 (USD Million & CAGR)
  • Figure 46: Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market Value, By End-Use, 2022 (USD Million)
  • Figure 47: Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Distribution Channel, 2022 (%)
  • Figure 48: Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Route of Administration, By Value, 2022 (%)
  • Figure 49: Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By End-Use, 2022 (%)
  • Figure 50: Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Value, 2020-2030 (USD Million & CAGR)
  • Figure 51: Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Value, By End-Use, 2022 (USD Million)
  • Figure 52: Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Distribution Channel, 2022 (%)
  • Figure 53: Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Route of Administration, By Value, 2022 (%)
  • Figure 54: Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By End-Use, 2022 (%)
  • Figure 55: Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Value, 2020H-2030F (USD Million)
  • Figure 56: Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By End-Use, 2022 (%)
  • Figure 57: Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Clinics, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 58: Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 59: Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 60: Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 61: Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 62: Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Type 2 Diabetes, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 63: Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By NASH, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 64: Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Obesity, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 65: United Kingdom Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Value, 2020-2030 (USD Million & CAGR)
  • Figure 66: United Kingdom Glucagon-Like Peptide 1 (GLP-1) Agonist Market Value, By End-Use, 2022 (USD Million)
  • Figure 67: United Kingdom Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Distribution Channel, 2022 (%)
  • Figure 68: United Kingdom Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Route of Administration, By Value, 2022 (%)
  • Figure 69: United Kingdom Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By End-Use, 2022 (%)
  • Figure 70: Germany Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Value, 2020-2030 (USD Million & CAGR)
  • Figure 71: Germany Glucagon-Like Peptide 1 (GLP-1) Agonist Market Value, By End-Use, 2022 (USD Million)
  • Figure 72: Germany Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Distribution Channel, 2022 (%)
  • Figure 73: Germany Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Route of Administration, By Value, 2022 (%)
  • Figure 74: Germany Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By End-Use, 2022 (%)
  • Figure 75: France Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Value, 2020-2030 (USD Million & CAGR)
  • Figure 76: France Glucagon-Like Peptide 1 (GLP-1) Agonist Market Value, By End-Use, 2022 (USD Million)
  • Figure 77: France Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Distribution Channel, 2022 (%)
  • Figure 78: France Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Route of Administration, By Value, 2022 (%)
  • Figure 79: France Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By End-Use, 2022 (%)
  • Figure 80: Italy Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Value, 2020-2030 (USD Million & CAGR)
  • Figure 81: Italy Glucagon-Like Peptide 1 (GLP-1) Agonist Market Value, By End-Use, 2022 (USD Million)
  • Figure 82: Italy Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Distribution Channel, 2022 (%)
  • Figure 83: Italy Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Route of Administration, By Value, 2022 (%)
  • Figure 84: Italy Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By End-Use, 2022 (%)
  • Figure 85: Rest of Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Value, 2020-2030 (USD Million & CAGR)
  • Figure 86: Rest of Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Value, By End-Use, 2022 (USD Million)
  • Figure 87: Rest of Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Distribution Channel, 2022 (%)
  • Figure 88: Rest of Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Route of Administration, By Value, 2022 (%)
  • Figure 89: Rest of Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By End-Use, 2022 (%)
  • Figure 90: Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Value, 2020H-2030F (USD Million)
  • Figure 91: Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By End-Use, 2022 (%)
  • Figure 92: Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Clinics, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 93: Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 94: Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 95: Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 96: Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 97: Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Type 2 Diabetes, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 98: Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By NASH, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 99: Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Obesity, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 100: China Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Value, 2020-2030 (USD Million & CAGR)
  • Figure 101: China Glucagon-Like Peptide 1 (GLP-1) Agonist Market Value, By End-Use, 2022 (USD Million)
  • Figure 102: China Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Distribution Channel, 2022 (%)
  • Figure 103: China Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Route of Administration, By Value, 2022 (%)
  • Figure 104: China Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By End-Use, 2022 (%)
  • Figure 105: Japan Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Value, 2020-2030 (USD Million & CAGR)
  • Figure 106: Japan Glucagon-Like Peptide 1 (GLP-1) Agonist Market Value, By End-Use, 2022 (USD Million)
  • Figure 107: Japan Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Distribution Channel, 2022 (%)
  • Figure 108: Japan Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Route of Administration, 2022 (%)
  • Figure 109: Japan Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By End-Use, By Value, 2022 (%)
  • Figure 110: South Korea Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Value, 2020-2030 (USD Million & CAGR)
  • Figure 111: South Korea Glucagon-Like Peptide 1 (GLP-1) Agonist Market Value, By End-Use, 2022 (USD Million)
  • Figure 112: South Korea Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Distribution Channel, 2022 (%)
  • Figure 113: South Korea Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Route of Administration, 2022 (%)
  • Figure 114: South Korea Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By End-Use, By Value, 2022 (%)
  • Figure 115: India Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Value, 2020-2030 (USD Million & CAGR)
  • Figure 116: India Glucagon-Like Peptide 1 (GLP-1) Agonist Market Value, By End-Use, 2022 (USD Million)
  • Figure 117: India Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Distribution Channel, 2022 (%)
  • Figure 118: India Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Route of Administration, 2022 (%)
  • Figure 119: India Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By End-Use, By Value, 2022 (%)
  • Figure 120: Rest of Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Value, 2020-2030 (USD Million & CAGR)
  • Figure 121: Rest of Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Value, By End-Use, 2022 (USD Million)
  • Figure 122: Rest of Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Distribution Channel, 2022 (%)
  • Figure 123: Rest of Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By Route of Administration, 2022 (%)
  • Figure 124: Rest of Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By End-Use, By Value, 2022 (%)
  • Figure 125: Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Value, 2020H-2030F (USD Million)
  • Figure 126: Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Share, By End-Use, 2022 (%)
  • Figure 127: Middle East and Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Clinics, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 128: Middle East and Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 129: Middle East and Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 130: Middle East and Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 131: Middle East and Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 132: Middle East and Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Type 2 Diabetes, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 133: Middle East and Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By NASH, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 134: Middle East and Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Obesity, By Value, 2020H-2030F (USD Million & CAGR)
  • Figure 135: Market Share of Prominent Companies of Glucagon-Like Peptide 1 (GLP-1) Agonist Market, 2022 (%)
  • Figure 136: Eli Lilly and Company Revenues, 2020-2022 (USD Million)
  • Figure 137: Eli Lilly and Company Revenues, By Geographic Segments, 2022 (%)
  • Figure 138: Eli Lilly and Company Revenue, By Therapeutic Area, 2022 (%)
  • Figure 139: Pfizer Revenues, 2020-2022 (USD Million)
  • Figure 140: Pfizer Revenues, By Business Segments, 2022 (%)
  • Figure 141: Pfizer Inc. Revenue, By Geographical Segments, 2022 (%)
  • Figure 142: Sanofi Revenues, 2020-2022 (USD Million)
  • Figure 143: Sanofi Revenues, By Geographic Segments, 2022 (%)
  • Figure 144: Sanofi Revenue, By Business Segments, 2022 (%)
  • Figure 145: AstraZeneca PLC Revenues, 2020-2022 (USD Million)
  • Figure 146: AstraZeneca PLC Revenues, By Geographic Segments, 2022 (%)
  • Figure 147: AstraZeneca PLC Revenue, By Business Segments, 2022 (%)
  • Figure 148: Novo Nordisk Revenues, 2020-2022 (USD Million)
  • Figure 149: Novo Nordisk Revenues, By Geographic Segments, 2022 (%)
  • Figure 150: Novo Nordisk Revenue, By Therapeutic Area, 2022 (%)

List of Tables

Table A1: Global Impact of Macro Economic Factors, By Region

Table A2: Details of GLP-1 Agonist in several stages of clinical trials

Table A3: United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2020-2023 (USD Million)

Table A4: United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2024-2030 (USD Million)

Table A5: United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A6: United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A7: United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2020-2023 (USD Million)

Table A8: United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2024-2030 (USD Million)

Table A9: Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2020-2023 (USD Million)

Table A10: Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2024-2030 (USD Million)

Table A11: Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A12: Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A13: Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2020-2023 (USD Million)

Table A14: Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2024-2030 (USD Million)

Table A15: Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2020-2023 (USD Million)

Table A16: Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2024-2030 (USD Million)

Table A17: Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A18: Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A19: Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2020-2023 (USD Million)

Table A20: Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2024-2030 (USD Million)

Table A21: United Kingdom Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2020-2023 (USD Million)

Table A22: United Kingdom Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2024-2030 (USD Million)

Table A23: United Kingdom Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A24: United Kingdom Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A25: United Kingdom Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2020-2023 (USD Million)

Table A26: United Kingdom Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2024-2030 (USD Million)

Table A27: Germany Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2020-2023 (USD Million)

Table A28: Germany Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2024-2030 (USD Million)

Table A29: Germany Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A30: Germany Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A31: Germany Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2020-2023 (USD Million)

Table A32: Germany Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2024-2030 (USD Million)

Table A33: France Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2020-2023 (USD Million)

Table A34: France Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2024-2030 (USD Million)

Table A35: France Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A36: France Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A37: France Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2020-2023 (USD Million)

Table A38: France Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2024-2030 (USD Million)

Table A39: Italy Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2020-2023 (USD Million)

Table A40: Italy Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2024-2030 (USD Million)

Table A41: Italy Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A42: Italy Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A43: Italy Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2020-2023 (USD Million)

Table A44: Italy Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2024-2030 (USD Million)

Table A45: Rest of Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2020-2023 (USD Million)

Table A46: Rest of Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2024-2030 (USD Million)

Table A47: Rest of Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A48: Rest of Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A49: Rest of Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2020-2023 (USD Million)

Table A50: Rest of Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2024-2030 (USD Million)

Table A51: China Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2020-2023 (USD Million)

Table A52: China Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2024-2030 (USD Million)

Table A53: China Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A54: China Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A55: China Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2020-2023 (USD Million)

Table A56: China Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2024-2030 (USD Million)

Table A57: Japan Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2020-2023 (USD Million)

Table A58: Japan Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2024-2030 (USD Million)

Table A59: Japan Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A60: Japan Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A61: Japan Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2020-2023 (USD Million)

Table A62: Japan Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2024-2030 (USD Million)

Table A63: South Korea Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2020-2023 (USD Million)

Table A64: South Korea Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2024-2030 (USD Million)

Table A65: South Korea Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A66: South Korea Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A67: South Korea Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2020-2023 (USD Million)

Table A68: South Korea Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2024-2030 (USD Million)

Table A69: India Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2020-2023 (USD Million)

Table A70: India Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2024-2030 (USD Million)

Table A71: India Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A72: India Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A73: India Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2020-2023 (USD Million)

Table A74: India Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2024-2030 (USD Million)

Table A75: Rest of Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2020-2023 (USD Million)

Table A76: Rest of Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel, By Value, 2024-2030 (USD Million)

Table A77: Rest of Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A78: Rest of Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A79: Rest of Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2020-2023 (USD Million)

Table A80: Rest of Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use, By Value, 2024-2030 (USD Million)

Table A81: Eli Lilly and Company Key Financials, 2020-2022

Table A82: Pfizer Key Financials, 2020-2022

Table A83: Sanofi Key Financials, 2020-2022

Table A84: AstraZeneca PLC Key Financials, 2020-2022

Table A85: Novo Nordisk Key Financials, 2020-2022

目次

Executive Summary

Azoth Analytics has released a research report titled "Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market (2024 Edition)" which provides a complete analysis of the Global Glucagon-Like Peptide 1 (GLP-1) Agonist industry in terms of market segmentation By Type (Tirzepatide, Semaglutide, Dulaglutide, and Other Types), By Distribution Channel (Clinics, Ambulatory Surgical Centers, and Hospitals), By Route of Administration (Oral, and Parenteral) By End-Use (Type 2 Diabetes, NASH, and Obesity), for the historical period of 2020-2023, the estimates of 2023 and the forecast period of 2024-2030.

The research report covers a detailed analysis of the Region (Americas, Europe, Asia Pacific, and Middle East and Africa) and Countries (United States, Canada, UK, Germany, France, Italy, India, China, Japan, South Korea). Additionally, the research report presents data including market size, yearly growth & potential analysis, the competitive study of market players, investment opportunities, and demand forecast. The research report also assesses growth indicators, restraints, supply and demand risk, and other important statistics, as well as a full assessment of current and future market trends that are relevant to the market evolution.

The Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market showcased growth at a CAGR of 20.6% during 2020-2023. The market was valued at USD 18.75 Billion in 2022 which is expected to reach USD 133.5 Billion in 2030. The demand for GLP-1 agonists extends globally, with both developed and developing regions contributing to market growth. Emerging economies are witnessing a rising prevalence of T2DM, driving the need for effective diabetes management strategies, including GLP-1 agonist therapies. The market includes a variety of GLP-1 agonist drugs, both short-acting and long-acting formulations, offering different options for healthcare providers and patients. These drugs are administered via subcutaneous injection or, in some cases, orally.

GLP-1 agonists are known for their efficacy in improving glycemic control in patients with T2DM, often leading to reductions in HbA1c levels and fasting plasma glucose levels. Additionally, these drugs are associated with weight loss, making them particularly beneficial for obese individuals with diabetes.

Several GLP-1 agonists have demonstrated cardiovascular benefits in clinical trials, including reductions in major adverse cardiovascular events (MACE) such as heart attack, stroke, and cardiovascular death. These findings have contributed to the growing adoption of GLP-1 agonists in patients with T2DM and established cardiovascular disease (CVD) or high cardiovascular risk.

While GLP-1 agonists are primarily administered via subcutaneous injections, efforts are underway to develop alternative delivery methods, such as oral formulations and once-weekly injections, to improve patient adherence and convenience. These innovations aim to address potential barriers to treatment adherence and enhance patient satisfaction.

Scope of the Report

  • The report analyses the Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market by Value (USD Million).
  • The report presents the analysis of the Global Glucagon-Like Peptide 1 (GLP-1) Agonist market for the historical period of 2020-2023, the estimated year 2023, and the forecast period of 2024-2030.
  • The report analyses the Global Glucagon-Like Peptide 1 (GLP-1) Agonist market by Type (Tirzepatide, Semaglutide, Dulaglutide, and Other Types).
  • The report analyses the Global Glucagon-Like Peptide 1 (GLP-1) Agonist market by Distribution Channel (Clinics, Ambulatory Surgical Centers, and Hospitals).
  • The report analyses the Global Glucagon-Like Peptide 1 (GLP-1) Agonist market by Route of Administration (Oral, and Parenteral).
  • The report analyses the Global Glucagon-Like Peptide 1 (GLP-1) Agonist market by End-Use (Type 2 Diabetes, NASH, and Obesity).
  • The key insights of the report have been presented through the frameworks of SWOT and Porter's Five Forces Analysis. Also, the attractiveness of the market has been presented by region, By Type, By Distribution Channel, By Route of Administration & By End-Use.
  • Also, the major opportunities, trends, drivers, and challenges of the industry have been analyzed in the report.
  • The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analyzed in the report include Eli Lilly and Company, Pfizer, Sanofi, AstraZeneca PLC, Boehringer Ingelheim, and Novo Nordisk.

Table of Contents

1. Market Background

  • 1.1 Scope and Product Outlook
  • 1.2 Executive Summary
  • 1.3 Research Methodology

2. Strategic Recommendations

3. Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Historic and Forecast (2020-2030)

  • 3.1 Impact Analysis of Macro Economic Factors on Glucagon-Like Peptide 1 (GLP-1) Agonist Market
  • 3.2 Pipeline Analysis of GLP-1 Agonist Market
  • 3.3 Global Obesity Statistics 2022, in Millions
  • 3.4 Diabetes Statistics
  • 3.5 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Dashboard
  • 3.6 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Value Assessment, 2020-2030 (USD Million)
  • 3.7 Impact of COVID-19 on Glucagon-Like Peptide 1 (GLP-1) Agonist Market
  • 3.8 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Type
    • 3.8.1 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Type Overview
    • 3.8.2 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Tirzepatide, By Value, 2020H-2030F (USD Million & CAGR)
    • 3.8.3 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Semaglutide, By Value, 2020H-2030F (USD Million & CAGR)
    • 3.8.4 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Dulaglutide, By Value, 2020H-2030F (USD Million & CAGR)
    • 3.8.5 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Other Types, By Value, 2020H-2030F (USD Million & CAGR)
  • 3.9 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Distribution Channel
    • 3.9.1 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel Overview
    • 3.9.2 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Clinics, By Value, 2020H-2030F (USD Million & CAGR)
    • 3.9.3 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Million & CAGR)
    • 3.9.4 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
  • 3.10 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Route of Administration
    • 3.10.1 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration Overview
    • 3.10.2 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
    • 3.10.3 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
  • 3.11 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By End-Use
    • 3.11.1 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use Overview
    • 3.11.2 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Type 2 Diabetes, By Value, 2020H-2030F (USD Million & CAGR)
    • 3.11.3 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By NASH, By Value, 2020H-2030F (USD Million & CAGR)
    • 3.11.4 Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Obesity, By Value, 2020H-2030F (USD Million & CAGR)

4. Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Regional Analysis

  • 4.1 Regional Coverage of the Study
  • 4.2 Regional Snapshot

5. Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Historic and Forecast (2020-2030)

  • 5.1 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Snapshot
  • 5.2 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Value Assessment, 2020-2030 (USD Million & CAGR)
  • 5.3 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Key Factors
  • 5.4 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Value Assessment
  • 5.5 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Dynamics
  • 5.6 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Distribution Channel
    • 5.6.1 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel Overview
    • 5.6.2 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Clinics, By Value, 2020H-2030F (USD Million & CAGR)
    • 5.6.3 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Million & CAGR)
    • 5.6.4 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
  • 5.7 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Route of Administration
    • 5.7.1 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration Overview
    • 5.7.2 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
    • 5.7.3 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
  • 5.8 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By End-Use
    • 5.8.1 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use Overview
    • 5.8.2 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Type 2 Diabetes, By Value, 2020H-2030F (USD Million & CAGR)
    • 5.8.3 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By NASH, By Value, 2020H-2030F (USD Million & CAGR)
    • 5.8.4 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Obesity, By Value, 2020H-2030F (USD Million & CAGR)
  • 5.9 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Country
    • 5.9.1 Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Country Overview
    • 5.9.2 United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
      • 5.9.2.1 United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel
      • 5.9.2.2 United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration
      • 5.9.2.3 United States Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use
    • 5.9.3 Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
      • 5.9.3.1 Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use
      • 5.9.3.2 Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration
      • 5.9.3.3 Canada Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel
    • 5.9.4 Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
      • 5.9.4.1 Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use
      • 5.9.4.2 Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration
      • 5.9.4.3 Rest of Americas Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel

6. Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Historic and Forecast (2020-2030)

  • 6.1 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Snapshot
  • 6.2 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Value Assessment, 2020-2030 (USD Million & CAGR)
  • 6.3 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Key Factors
  • 6.4 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Value Assessment
  • 6.5 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Dynamics
  • 6.6 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Distribution Channel
    • 6.6.1 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel Overview
    • 6.6.2 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Clinics, By Value, 2020H-2030F (USD Million & CAGR)
    • 6.6.3 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Million & CAGR)
    • 6.6.4 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
  • 6.7 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Route of Administration
    • 6.7.1 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration Overview
    • 6.7.2 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
    • 6.7.3 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
  • 6.8 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By End-Use
    • 6.8.1 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use Overview
    • 6.8.3 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Type 2 Diabetes, By Value, 2020H-2030F (USD Million & CAGR)
    • 6.8.4 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By NASH, By Value, 2020H-2030F (USD Million & CAGR)
    • 6.8.5 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Obesity, By Value, 2020H-2030F (USD Million & CAGR)
  • 6.9 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Country
    • 6.9.1 Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Country Overview
    • 6.9.2 United Kingdom Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
      • 6.9.2.1 United Kingdom Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel
      • 6.9.2.2 United Kingdom Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration
      • 6.9.2.3 United Kingdom Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use
    • 6.9.3 Germany Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
      • 6.9.3.1 Germany Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel
      • 6.9.3.2 Germany Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration
      • 6.9.3.3 Germany Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use
    • 6.9.4 France Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
      • 6.9.4.1 France Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel
      • 6.9.4.2 France Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration
      • 6.9.4.3 France Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use
    • 6.9.5 Italy Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
      • 6.9.5.1 Italy Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel
      • 6.9.5.2 Italy Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration
      • 6.9.5.3 Italy Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use
    • 6.9.6 Rest of Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
      • 6.9.6.1 Rest of Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel
      • 6.9.6.2 Rest of Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration
      • 6.9.6.3 Rest of Europe Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use

7. Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Historic and Forecast (2020-2030)

  • 7.1 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Snapshot
  • 7.2 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Value Assessment, 2020-2030 (USD Million & CAGR)
  • 7.3 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Key Factors
  • 7.4 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Value Assessment
  • 7.5 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Dynamics
  • 7.6 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Distribution Channel
    • 7.6.1 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel Overview
    • 7.6.2 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Clinics, By Value, 2020H-2030F (USD Million & CAGR)
    • 7.6.3 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Million & CAGR)
    • 7.6.4 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
  • 7.7 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Route of Administration
    • 7.7.1 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration Overview
    • 7.7.2 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
    • 7.7.3 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
  • 7.8 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By End-Use
    • 7.8.1 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use Overview
    • 7.8.2 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Type 2 Diabetes, By Value, 2020H-2030F (USD Million & CAGR)
    • 7.8.3 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By NASH, By Value, 2020H-2030F (USD Million & CAGR)
    • 7.8.4 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Obesity, By Value, 2020H-2030F (USD Million & CAGR)
  • 7.9 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Country
    • 7.9.1 Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Country Overview
    • 7.9.2 China Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
      • 7.9.2.1 China Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel
      • 7.9.2.2 China Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration
      • 7.9.2.3 China Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use
    • 7.9.3 Japan Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
      • 7.9.3.1 Japan Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel
      • 7.9.3.2 Japan Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration
      • 7.9.3.3 Japan Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use
    • 7.9.4 South Korea Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
      • 7.9.4.1 South Korea Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel
      • 7.9.4.2 South Korea Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration
      • 7.9.4.3 South Korea Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use
    • 7.9.5 India Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
      • 7.9.5.1 India Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel
      • 7.9.5.2 India Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration
      • 7.9.5.3 India Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use
    • 7.9.6 Rest of Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
      • 7.9.6.1 Rest of Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel
      • 7.9.6.2 Rest of Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration
      • 7.9.6.3 Rest of Asia Pacific Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use

8. Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Historic and Forecast (2020-2030)

  • 8.1 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Snapshot
  • 8.2 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Value Assessment, 2020-2030 (USD Million & CAGR)
  • 8.3 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Key Factors
  • 8.4 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Value Assessment
  • 8.5 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Dynamics
  • 8.6 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Distribution Channel
    • 8.6.1 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel Overview
    • 8.6.2 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Clinics, By Value, 2020H-2030F (USD Million & CAGR)
    • 8.6.3 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Million & CAGR)
    • 8.6.4 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
  • 8.7 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Route of Administration
    • 8.7.1 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration Overview
    • 8.7.2 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
    • 8.7.3 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
  • 8.8 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By End-Use
    • 8.8.1 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use Overview
    • 8.8.2 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Type 2 Diabetes, By Value, 2020H-2030F (USD Million & CAGR)
    • 8.8.3 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By NASH, By Value, 2020H-2030F (USD Million & CAGR)
    • 8.8.4 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Obesity, By Value, 2020H-2030F (USD Million & CAGR)

9. Market Dynamics

  • 9.1 Impact Assessment of Market Dynamics on Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market
  • 9.2 Drivers
  • 9.3 Restraints
  • 9.4 Trends

10. Industry Ecosystem Analysis

  • 10.1 Porter's Five Forces Model

11. Competitive Positioning

  • 11.1 Companies' Product Positioning
  • 11.2 Market Share Analysis of Glucagon-Like Peptide 1 (GLP-1) Agonist Market
  • 11.3 Company Profiles
    • 11.3.1 Eli Lilly and Company
    • 11.3.2 Pfizer
    • 11.3.3 Sanofi
    • 11.3.4 AstraZeneca PLC
    • 11.3.5 Boehringer Ingelheim
    • 11.3.6 Novo Nordisk